Table 1.
Characteristics | AA (N = 947); n (%) | CA (N = 10,028); n (%) | p |
---|---|---|---|
Age at diagnosis (years) | <.0001 | ||
66-69 | 256 (27) | 1,907 (19) | |
70-74 | 362 (38) | 3,651 (36) | |
≥75 | 329 (35) | 4,470 (45) | |
Year of radiation | .977 | ||
2002 | 212 (22) | 2,198 (22) | |
2003 | 191 (20) | 2,109 (20) | |
2004 | 178 (19) | 1,863 (19) | |
2005 | 180 (19) | 1,876 (19) | |
2006 | 186 (20) | 1,982 (20) | |
Marital status | <.0001 | ||
Married | 535 (56) | 7,295 (73) | |
Not married/unknown | 412 (44) | 2,733 (37) | |
NCI combined comorbidity score | <.0001 | ||
0 | 478 (50) | 6,327 (63) | |
>0 | 469 (50) | 3,701 (37) | |
% census income | <.0001 | ||
0%-25% (low income) | 566 (60) | 2,256 (22) | |
26%-50% (low–medium income) | 209 (22) | 2,638 (26) | |
51%-75% (medium–high income) | 122 (13) | 2,567 (26) | |
>75% (High income) | 50 (5) | 2,567 (26) | |
% non–high school graduate in census tract | <.0001 | ||
0%-25% (low education) | 550 (58) | 2,157 (22) | |
26%-50% (low–medium education) | 218 (23) | 2,459 (25) | |
51%-75% (medium–high education) | 129 (14) | 2,756 (27) | |
>75% (high education) | 50 (5) | 2,656 (26) | |
Population density | .038 | ||
Urban | 898 (95) | 8,845 (88) | |
Rural | 49 (5) | 1,183 (12) | |
Tumor grade | |||
I | 478 (50) | 4,507 (45) | .002 |
II | 443 (47) | 5,127 (51) | |
III/IV | 26 (3) | 394 (4) | |
Clinical stage | .399 | ||
T1/T2 | 516 (54) | 5,607 (56) | |
T3/T4 | 431 (45) | 4,421 (44) | |
Treatment modality | <.0001 | ||
IMRT | 423 (45) | 5,282 (53) | |
CRT | 524 (55) | 4,746 (47) | |
Geographic region | <.0001 | ||
South | 252 (26) | 1,604 (16) | |
Northeast | 280 (30) | 2,871 (29) | |
Central | 272 (29) | 2,108 (21) | |
West | 143 (15) | 3,445 (34) |
Note. SEER = Surveillance, Epidemiology, and End Results; AA = African American; CA = Caucasian; NCI = National Cancer Institute; IMRT = intensity-modulated radiation therapy; CRT = conformal radiation therapy. SEER sites were grouped into four geographic regions for analysis.
a. Determined using the chi-square test.